What is the role of vismodegib in the management of basal cell carcinoma (BCC)?

Updated: Mar 23, 2021
  • Author: Robert S Bader, MD; Chief Editor: William D James, MD  more...
  • Print

Vismodegib (Erivedge) is the first FDA-approved drug for advanced forms of basal cell carcinoma (BCC). It selectively inhibits Smoothened (SMO), a key transmembrane protein involved in Hedgehog signal transduction of cancerous epithelial cells. [99] FDA approval was based on a single, international, open-label trial (n=104). Of the 104 participants, 96 were evaluable. Of those with metastatic BCC (n=33), 30.3% had partial response, but none had complete response. With locally advanced BCC (n=63), 22% showed a partial response and 20% showed complete response. [100]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!